Nasus Pharma Ltd. NSRX
3.48
0.00
0.00%
as of 25 Sep
- Market cap
- $40.8M
- P/E
- —
Follow NSRX
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Dec '25 | Jun '25 | Dec '24 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | — | — | — |
+1 more TTM period Free account |
|
| 0.00% | — | — | — | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
0.00 | 0.00 | — | — | |
Free Cash Flow |
(12.07) | (7.04) | — | — | |
Capital Expenditures |
(0.02) | — | — | — | |
Piotroski F-Score |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Cash ROIC |
(63.77%) | (173.56%) | 0.00% | 0.00% | |
Accounts Payable Turnover |
0.00 | — | — | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | — | — | |
Depreciation/Fixed assets |
0.00 | — | — | — | |
Capex/Depreciation |
0.00 | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | — | — | |
Capex per Share |
0.00 | — | — | — | |
Capex to Sales |
0.00 | — | — | — |
Columns are period end dates